Semax: What the Research Shows
Also known as: MEHFPGP, Heptapeptide ACTH analog
A synthetic peptide analog of ACTH(4-10) approved in Russia as a nootropic, studied for cognitive enhancement and neuroprotection.
This content is for educational purposes only and is not medical advice. Consult a qualified healthcare provider before making any health decisions. Full disclaimer
Quick Facts
Regulatory Status
Not FDA-approved. Approved in Russia and Ukraine as a nootropic and neuroprotective agent. Research compound in the US.
Researched Applications
Key Research (1 studies cited)
Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems
animalEremin KO, et al. (2005) — Neurochemical Research
Study showing semax activates both dopaminergic and serotonergic systems, providing a mechanism for its cognitive effects.
Key finding: Semax activated dopaminergic and serotonergic neurotransmission, suggesting mechanisms for its nootropic and antidepressant properties.
PubMed: 16258686About this article: Written by the PeptideMark Research Team. Last reviewed 2026-03-11. All factual claims are cited to peer-reviewed sources. PubMed links open in a new tab for independent verification. Editorial methodology · Medical disclaimer
The Peptide Brief
Weekly peptide research digest. No spam.